Investigating new treatments for high-grade serous ovarian cancer and triple-negative breast cancer
Protein arginine methyltransferase inhibitors in treatment of high-grade serous ovarian cancer and triple-negative breast cancer
This study is looking at how certain proteins in high-grade serous ovarian cancer and triple-negative breast cancer affect treatment, and it’s testing new drugs that could work better when combined with other therapies to help improve outcomes for patients.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Pennsylvania NIH-funded |
| Lab location | 1 site (Philadelphia, United States) |
| Project ID | NIH-10976793 on NIH RePORTER |
What this research studies
This research focuses on the role of protein arginine methyltransferases (PRMTs) in high-grade serous ovarian cancer and triple-negative breast cancer. It aims to evaluate new inhibitors that target these proteins, which are found at elevated levels in cancer cells and linked to poor outcomes. The study will explore how these inhibitors can be combined with other therapies to improve treatment effectiveness. Patients may benefit from a better understanding of how to use these new drugs in combination with existing treatments.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with high-grade serous ovarian cancer or triple-negative breast cancer.
Not a fit: Patients with other types of cancer or those who do not have high-grade serous ovarian cancer or triple-negative breast cancer may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatment options for patients with high-grade serous ovarian cancer and triple-negative breast cancer.
How similar studies have performed: Other research has shown promise in targeting PRMTs in cancer treatment, indicating that this approach could be a meaningful advancement in oncology.
Where this research is happening
Philadelphia, United States
- University of Pennsylvania — Philadelphia, United States (Active)
Researchers
- Principal investigator: Zhang, Lin — University of Pennsylvania
- Study coordinator: Zhang, Lin
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.